Table 5.
Median overall survival (OS) and progression-free survival (PFS) for the overall group of patients with SDHx mutation including both subgroups SDHD and SDHB, hormonal status in entry into the study, presence of liver and bone involvement and also clinical response evaluated six weeks after PRRT as partial response (PR), stable disease (SD) or disease progression (PD). Abbreviation: N.R. not reached.
| Variable | Subjects | Median OS Months (+/−95% CI) |
P-value | Median PFS Months (+/−95% CI) |
p-Value |
|---|---|---|---|---|---|
| All subjects | 13 | 68.0 (38.6–105.1) | 35.0 (24.4–93.1) | ||
| Mutation | 0.05 | 0.014 | |||
| SDHD | 8 | N.R. (not reached) | N.R. (not reached) | ||
| SDHB | 5 | 25.0 (3.2–85.6) | 12.0 (2.3–48.8) | ||
| Clinical response | 0.005 | 0.0004 | |||
| PR | 8 | N.R. (not reached) | N.R. (not reached) | ||
| SD/DP | 5 | 22.0 (6.5–27.9) | 7.0 (3.8–11.8) | ||
| Liver mts | 0.033 | 0.005 | |||
| present | 7 | 25.0 (6.0–67.7) | 10.0 (1.3–39.0) | ||
| absent | 6 | N.R. (not reached) | N.R. (not reached) | ||
| Bone mts | 0.029 | 0.0027 | |||
| present | 9 | 25.0 (14.1–71.9) | 12 (6.3–41.0) | ||
| absent | 4 | N.R. (not reached) | N.R. (not reached) | ||
| Hormonal status | 0.496 | 0.84 | |||
| secretor | 4 | 49.0 (0–152.4) | 27.0 (0–148.2) | ||
| non-secretor | 9 | 97.0 (30.0–120.1) | 60.0 (15.9–109.4) |